Grandeur Peak Global Advisors LLC Invests $15.45 Million in LeMaitre Vascular, Inc. $LMAT

Grandeur Peak Global Advisors LLC purchased a new stake in LeMaitre Vascular, Inc. (NASDAQ:LMAT - Free Report) in the second quarter, according to the company in its most recent Form 13F filing with the Securities & Exchange Commission. The firm purchased 161,010 shares of the medical instruments supplier's stock, valued at approximately $15,451,000. LeMaitre Vascular makes up 3.1% of Grandeur Peak Global Advisors LLC's investment portfolio, making the stock its 9th largest holding. Grandeur Peak Global Advisors LLC owned 0.70% of LeMaitre Vascular at the end of the most recent quarter.

A number of other hedge funds and other institutional investors have also recently added to or reduced their stakes in the company. Sound Income Strategies LLC increased its holdings in LeMaitre Vascular by 425.6% in the first quarter. Sound Income Strategies LLC now owns 226 shares of the medical instruments supplier's stock valued at $25,000 after purchasing an additional 183 shares during the last quarter. Catalyst Capital Advisors LLC acquired a new position in shares of LeMaitre Vascular in the first quarter valued at $32,000. Geneos Wealth Management Inc. lifted its position in LeMaitre Vascular by 250.3% during the first quarter. Geneos Wealth Management Inc. now owns 557 shares of the medical instruments supplier's stock worth $47,000 after acquiring an additional 398 shares during the last quarter. EverSource Wealth Advisors LLC acquired a new position in shares of LeMaitre Vascular in the second quarter valued at approximately $47,000. Finally, Quarry LP lifted its holdings in LeMaitre Vascular by 267.2% during the 3rd quarter. Quarry LP now owns 727 shares of the medical instruments supplier's stock worth $64,000 after purchasing an additional 529 shares during the last quarter. 84.64% of the stock is currently owned by institutional investors and hedge funds.

LeMaitre Vascular Stock Performance

Shares of LMAT opened at $79.67 on Friday. LeMaitre Vascular, Inc. has a 52 week low of $78.27 and a 52 week high of $118.01. The company has a debt-to-equity ratio of 0.40, a quick ratio of 13.96 and a current ratio of 16.31. The firm has a market capitalization of $1.82 billion, a P/E ratio of 27.95, a P/E/G ratio of 2.30 and a beta of 0.53. The stock has a 50 day moving average price of $93.31 and a two-hundred day moving average price of $99.46.

LeMaitre Vascular (NASDAQ:LMAT - Get Free Report) last announced its earnings results on Tuesday, August 4th. The medical instruments supplier reported $0.74 earnings per share for the quarter, missing analysts' consensus estimates of $0.81 by ($0.07). The business had revenue of $70.38 million during the quarter, compared to analysts' expectations of $71.47 million. LeMaitre Vascular had a return on equity of 15.63% and a net margin of 25.02%.LeMaitre Vascular's quarterly revenue was up 9.6% on a year-over-year basis. During the same quarter in the previous year, the firm earned $0.60 EPS. Equities analysts forecast that LeMaitre Vascular, Inc. will post 2.89 earnings per share for the current fiscal year.

LeMaitre Vascular Dividend Announcement

The company also recently announced a quarterly dividend, which will be paid on Thursday, September 3rd. Shareholders of record on Thursday, August 20th will be paid a $0.25 dividend. The ex-dividend date is Thursday, August 20th. This represents a $1.00 annualized dividend and a dividend yield of 1.3%. LeMaitre Vascular's payout ratio is presently 35.09%.

Analysts Set New Price Targets

A number of equities research analysts have recently issued reports on the stock. Citigroup reissued a "market outperform" rating on shares of LeMaitre Vascular in a research report on Tuesday, July 21st. Zacks Research lowered LeMaitre Vascular from a "strong-buy" rating to a "hold" rating in a research note on Monday, July 6th. Wells Fargo & Company reduced their price objective on LeMaitre Vascular from $104.00 to $94.00 and set an "equal weight" rating on the stock in a research report on Wednesday, August 5th. Barrington Research downgraded shares of LeMaitre Vascular from an "outperform" rating to a "market perform" rating in a research report on Wednesday, August 5th. Finally, Wall Street Zen lowered LeMaitre Vascular from a "buy" rating to a "hold" rating in a research report on Saturday, August 1st. Three investment analysts have rated the stock with a Buy rating and six have assigned a Hold rating to the company's stock. Based on data from MarketBeat.com, LeMaitre Vascular presently has a consensus rating of "Hold" and an average target price of $110.60.

About LeMaitre Vascular

LeMaitre Vascular, Inc is a specialty medical device company focused on the development, manufacture and marketing of products for the treatment of peripheral vascular disease. Headquartered in Burlington, Massachusetts, the company's offerings include a broad portfolio of vascular surgical instruments, grafts, patches, catheters and embolic protection devices. LeMaitre's product lines address key areas such as arterial reconstruction, endovascular repair and vascular access, serving the needs of cardiovascular surgeons and interventional specialists.

Founded in 1983 by George D.

This instant news alert was generated by narrative science technology and financial data from MarketBeat in order to provide readers with the fastest reporting and unbiased coverage. Please send any questions or comments about this story to contact@marketbeat.com.

Continue following MarketBeat

Add MarketBeat as your preferred source on Google to see our latest stories in your feed.

Add As Preferred Source